Literature DB >> 15979880

Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain.

Minna A Korolainen1, Seppo Auriola, Tuula A Nyman, Irina Alafuzoff, Tuula Pirttilä.   

Abstract

Chronic inflammation is known to play an important role in the heterogeneous pathogenesis of Alzheimer's disease (AD). Activated astrocytes expressing glial fibrillary acidic protein (GFAP) are closely associated with AD pathology, such as tangles, neuritic plaques and amyloid depositions. Altogether, 46 soluble isoforms of GFAP were separated and most of them quantified by two-dimensional immunoblotting in frontal cortices of AD patients and age-matched controls. A 60% increase in the amount of more acidic isoforms of GFAP was observed in AD and these isoforms were both phosphorylated and N-glycosylated, while more basic isoforms were O-glycosylated and exhibited no quantitative differences between post-mortem AD and control brains. These data highlight the importance of exploring isoform-specific levels of proteins in pathophysiological conditions since modifications of proteins determine their activity state, localization, turnover and interaction with other molecules. Mechanisms, structures and functional consequences of modification of GFAP isoforms remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979880     DOI: 10.1016/j.nbd.2005.05.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  35 in total

1.  Identification of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients.

Authors:  Georgene W Hergenroeder; Anthony N Moore; Karl M Schmitt; John B Redell; Pramod K Dash
Journal:  Neuroreport       Date:  2016-01-20       Impact factor: 1.837

2.  Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides.

Authors:  S G Torres-Platas; C Nagy; M Wakid; G Turecki; N Mechawar
Journal:  Mol Psychiatry       Date:  2015-06-02       Impact factor: 15.992

Review 3.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

4.  Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Authors:  Eduardo M Castaño; Chera L Maarouf; Terence Wu; Maria Celeste Leal; Charisse M Whiteside; Lih-Fen Lue; Tyler A Kokjohn; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  Neurochem Int       Date:  2012-12-08       Impact factor: 3.921

5.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Authors:  Joshua B Owen; Fabio Di Domenico; Rukhsana Sultana; Marzia Perluigi; Chiara Cini; William M Pierce; D Allan Butterfield
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

6.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

7.  Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims.

Authors:  N Tannu; D C Mash; S E Hemby
Journal:  Mol Psychiatry       Date:  2006-10-31       Impact factor: 15.992

Review 8.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

9.  HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.

Authors:  María-Salud García-Ayllón; Arancha Botella-López; Inmaculada Cuchillo-Ibañez; Alberto Rábano; Niels Andreasen; Kaj Blennow; Jesús Ávila; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2016-01-06       Impact factor: 5.590

10.  Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Authors:  Fabio Di Domenico; Raffaella Coccia; Annalisa Cocciolo; M Paul Murphy; Giovanna Cenini; Elizabeth Head; D Allan Butterfield; Alessandra Giorgi; Maria Eugenia Schinina; Cesare Mancuso; Chiara Cini; Marzia Perluigi
Journal:  Biochim Biophys Acta       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.